Thawing of Pharma Budgets Giving Lift to Proteomics Tool Vendors, but Will It Last? | GenomeWeb
After several years of frozen business with pharmaceutical firms, proteomics tool vendors are cautiously optimistic that demand from that market may be on the rise again.
No one is saying there’s been a return to the free-spending days of the late-90s to the early part of the millennium — a time that tool vendors recall with dewy fondness  — and most are loath to predict how long the upward spending trend may last.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.